An observational study in Papillary Thyroid Cancers, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Thyroid Cancer, Papillary with a site in United States — 8 open to participants now, 18 under way, 1 of them phase 3. Thyroid Cancer, Papillary · United States.
Among the 76 studies in Thyroid Cancer, Papillary with a site in United States, this one is the only one that started in 2027, is one of 9 observational ones, reaches primary completion later than 16 of the 16 other live ones, and was the 76th registered.
187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.
Browse Thyroid Cancer, Papillary studies →8 of the 76 studies in Thyroid Cancer, Papillary with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Jochen Lorch · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 6 mo–98 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 42 · Phase 3 2
First in 1977; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is below the median of 200 across 67 observational studies indexed under Thyroid Cancer, Papillary.
Median enrollment 25 across the 62 interventional studies, 50 across the 9 observational. Of the 55 that completed or were terminated, 29 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 76 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 5 studies filed under Thyroid Cancer, Papillary — fewer than ten, so there is no comparison to draw.
6 of the studies in Thyroid Cancer, Papillary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06440850City of Hope Medical CenterVemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | 2026-11-22 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
| NCT07545837Mayo ClinicHealth and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors | 2027-06-30 |
| NCT05024929Children's Hospital of PhiladelphiaTargeted Therapy to Increase RAI Uptake in Metastatic DTC | 2027-07 |
| NCT04544111Memorial Sloan Kettering Cancer CenterPDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | 2027-09-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Thyroid Cancer, Papillary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is learn about the effects of Thyroid GuidePx® on papillary thyroid cancer treatment recommendations when the test result is disclosed after surgery.
Primary Objectives:
To determine the decision impact of Thyroid GuidePx® when results are disclosed postoperatively, defined across three prespecified decision domains:
Secondary Objectives:
UT MD Anderson
Inclusion Criteria:
disease who can potentially be treated with lobectomy will be recruited to the study. Lobectomy-candidate status is determined by the treating physician using standard institutional criteria (e.g., tumor 1-4 cm, cN0/Nx, no gross ETE). Patients may still undergo total thyroidectomy as part of shared decision-making.
Inclusion criteria:
Preoperative candidacy for lobectomy
Any of the following intraoperative or surgeon-dependent variations are permitted:
Exclusion Criteria:
Patients remain eligible if unexpected central nodal disease is identified intraoperatively or if the surgeon elects to perform a prophylactic ipsilateral central neck dissection, as these scenarios are compatible with initial lobectomy candidacy at MD Anderson.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will be identified during standard preoperative evaluation for thyroid nodules or confirmed PTC, following cytological diagnosis (Bethesda V or VI).
Procedure: Thyroid GuidePx
Participants will be offered enrollment in this study, in which Thyroid GuidePx® will be performed on an intraoperative FNA (ioFNA) collected during surgery, with results disclosed postoperatively.
Decision Impact. There are three domain-specific endpoints
Extent of initial surgery (counterfactual). (i) Among patients who actually had total thyroidectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, would have changed surgical extent. Specifically, if lobectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential de-escalation. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation. b) Completion thyroidectomy. Proportion with a change in recommendation (Yes→No or No→Yes). c) Adjuvant RAI. Proportion with a change in recommendation (Yes→No or No→Yes) and intended dose if Yes.
Time frame: Through study completion; an average of 1 year
Start is estimated for Mar 2027; primary completion for Jun 2029, 27 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.